FiercePharmaOriginal article
{"a":[{"_":"Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide","$":{"href":"/manufacturing/samsung-biologics-spreads-wings-proposed-18b-acquisition-swiss-cdmo-polypeptide","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Samsung Biologics plans to acquire Swiss CDMO PolyPeptide for $1.8 billion to expand its peptide production capabilities and enter the weight loss market.
Outcome Details
Proposed acquisition of PolyPeptide by Samsung Biologics for 1.46 billion Swiss francs ($1.8 billion)
Importance:7/10
Sentiment:
0.60
M&ACDMOPeptide ProductionWeight LossContract Manufacturing
Read the original article
Published by FiercePharma on July 20, 2026 11:07 AM